导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.55% | 1071/4773 |
| 近一周 | -2.28% | 1660/5462 |
| 近一月 | -8.23% | 4162/5421 |
| 近一季 | -6.52% | 2122/5209 |
| 近半年 | -0.55% | 1330/4920 |
| 近一年 | 13.76% | 759/4366 |
| 近两年 | 101.85% | 595/2954 |
| 近三年 | 77.25% | 228/2253 |
| 成立以来 | 76.97% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.16% 2156/4961 |
29.85% 1010/5312 |
- - |
- - |
| 2025 | 52.40% 411/4813 |
2.29% 1413/3635 |
2.80% 1344/4076 |
44.56% 627/4524 |
0.26% 2097/4813 |
| 2024 | 12.68% 1221/3463 |
-1.30% 1210/2808 |
-0.18% 699/3014 |
11.41% 2525/3129 |
2.66% 912/3463 |
| 2023 | -1.70% 528/2656 |
14.88% 228/2280 |
0.09% 342/2385 |
-10.82% 2026/2515 |
-4.14% 884/2655 |
| 2022 | -24.16% 1197/2207 |
-17.62% 1229/1919 |
4.57% 997/2016 |
-15.07% 1205/2113 |
3.66% 659/2208 |
| 2021 | 19.95% 188/1822 |
-3.49% 809/1255 |
17.55% 185/1330 |
-0.32% 488/1466 |
6.08% 241/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证科技100指数增强发起C VS. 长安沪深300非周期A(740101) |